Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
A PHASE2 clinical study on Metabolic Disease and Seizures, this trial is completed. The trial is conducted by National Institute of Neurological Disorders and Stroke (NINDS) and has accumulated 12 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE2
-
May 2019 — Mar 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Mar 2019 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Aug 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Mar 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Neurological Disorders and Stroke (NINDS)
For direct contact, visit the study record on ClinicalTrials.gov .